{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:06:22Z","timestamp":1793480782999,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72074142"],"award-info":[{"award-number":["72074142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40261-025-01477-0","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T07:21:27Z","timestamp":1758093687000},"page":"681-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review"],"prefix":"10.1007","volume":"45","author":[{"given":"Kaijie","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6696-7471","authenticated-orcid":false,"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"1477_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"Y-C Hsu","year":"2023","unstructured":"Hsu Y-C, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20:524\u201337. https:\/\/doi.org\/10.1038\/s41575-023-00760-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"1477_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"BS Sheena","year":"2022","unstructured":"Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796\u2013829. https:\/\/doi.org\/10.1016\/S2468-1253(22)00124-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1477_CR3","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","volume":"224","author":"J Pattyn","year":"2021","unstructured":"Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccines. J Infect Dis. 2021;224:S343\u201351. https:\/\/doi.org\/10.1093\/infdis\/jiaa668.","journal-title":"J Infect Dis"},{"key":"1477_CR4","unstructured":"WHO. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis. https:\/\/www.who.int\/publications\/i\/item\/WHO-HIV-2016.06. Accessed 20 Aug 2025."},{"key":"1477_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40353","volume":"6","author":"P Li","year":"2023","unstructured":"Li P, Wang Y, Yu J, Yu J, Tao Q, Zhang J, et al. Tenofovir vs entecavir among patients with HBV-related HCC after resection. JAMA Netw Open. 2023;6:e2340353. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.40353.","journal-title":"JAMA Netw Open"},{"key":"1477_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.21037\/atm.2016.09.19","volume":"4","author":"F Tacke","year":"2016","unstructured":"Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med. 2016;4:334. https:\/\/doi.org\/10.21037\/atm.2016.09.19.","journal-title":"Ann Transl Med"},{"key":"1477_CR7","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3748\/wjg.v24.i17.1919","volume":"24","author":"WH Cho","year":"2018","unstructured":"Cho WH, Lee HJ, Bang KB, Kim SB, Song IH. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-na\u00efve chronic hepatitis B: a case report and review of the literature. World J Gastroenterol. 2018;24:1919\u201324. https:\/\/doi.org\/10.3748\/wjg.v24.i17.1919.","journal-title":"World J Gastroenterol"},{"key":"1477_CR8","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1002\/hep.22956","volume":"49","author":"R Perrillo","year":"2009","unstructured":"Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology. 2009;49:S103\u201311. https:\/\/doi.org\/10.1002\/hep.22956.","journal-title":"Hepatology"},{"key":"1477_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/hep4.1875","volume":"6","author":"HSJ Choi","year":"2022","unstructured":"Choi HSJ, Tonthat A, Janssen HLA, Terrault NA. Aiming for functional cure with established and novel therapies for chronic hepatitis B. Hepatol Commun. 2022;6:935\u201349. https:\/\/doi.org\/10.1002\/hep4.1875.","journal-title":"Hepatol Commun"},{"key":"1477_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","volume":"20","author":"SG Lim","year":"2023","unstructured":"Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol. 2023;20:238\u201353. https:\/\/doi.org\/10.1038\/s41575-022-00724-5.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1477_CR11","unstructured":"WHO. Global hepatitis report, 2017. https:\/\/www.who.int\/publications\/i\/item\/9789241565455. Accessed 20 Aug 2025."},{"key":"1477_CR12","doi-asserted-by":"publisher","unstructured":"Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatol Baltim Md 2018;67:1560. https:\/\/doi.org\/10.1002\/hep.29800.","DOI":"10.1002\/hep.29800"},{"key":"1477_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021.","journal-title":"J Hepatol"},{"key":"1477_CR14","doi-asserted-by":"publisher","first-page":"e060142","DOI":"10.1136\/bmjopen-2021-060142","volume":"12","author":"A Kjelsnes","year":"2022","unstructured":"Kjelsnes A, Feiring E. Models of integrated care for older people with frailty: a horizon scanning review. BMJ Open. 2022;12:e060142. https:\/\/doi.org\/10.1136\/bmjopen-2021-060142.","journal-title":"BMJ Open"},{"key":"1477_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.molmed.2022.06.002","volume":"28","author":"L-Y Mak","year":"2022","unstructured":"Mak L-Y, Cheung K-S, Fung J, Seto W-K, Yuen M-F. New strategies for the treatment of chronic hepatitis B. Trends Mol Med. 2022;28:742\u201357. https:\/\/doi.org\/10.1016\/j.molmed.2022.06.002.","journal-title":"Trends Mol Med"},{"key":"1477_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/17474124.2023.2268503","volume":"17","author":"B Laup\u00e8ze","year":"2023","unstructured":"Laup\u00e8ze B, Vassilev V, Badur S. A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments. Expert Rev Gastroenterol Hepatol. 2023;17:1135\u201347. https:\/\/doi.org\/10.1080\/17474124.2023.2268503.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1477_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/liv.14364","volume":"40","author":"MG Martinez","year":"2020","unstructured":"Martinez MG, Villeret F, Testoni B, Zoulim F. Can we cure hepatitis B virus with novel direct-acting antivirals? Liver Int. 2020;40:27\u201334. https:\/\/doi.org\/10.1111\/liv.14364.","journal-title":"Liver Int"},{"key":"1477_CR18","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/jcm9103187","volume":"9","author":"A Alexopoulou","year":"2020","unstructured":"Alexopoulou A, Vasilieva L, Karayiannis P. New approaches to the treatment of chronic hepatitis B. J Clin Med. 2020;9:3187. https:\/\/doi.org\/10.3390\/jcm9103187.","journal-title":"J Clin Med"},{"key":"1477_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21505594.2022.2093444","volume":"13","author":"S Phillips","year":"2022","unstructured":"Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for chronic hepatitis B. Virulence. 2022;13:1111\u201332. https:\/\/doi.org\/10.1080\/21505594.2022.2093444.","journal-title":"Virulence"},{"key":"1477_CR20","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/apt.16828","volume":"55","author":"D Yardeni","year":"2022","unstructured":"Yardeni D, Ghany MG. Review article: hepatitis B: current and emerging therapies. Aliment Pharmacol Ther. 2022;55:805\u201319. https:\/\/doi.org\/10.1111\/apt.16828.","journal-title":"Aliment Pharmacol Ther"},{"key":"1477_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3350\/cmh.2021.0093","volume":"28","author":"SW Kim","year":"2022","unstructured":"Kim SW, Yoon JS, Lee M, Cho Y. Toward a complete cure for chronic hepatitis B: novel therapeutic targets for hepatitis B virus. Clin Mol Hepatol. 2022;28:17\u201330. https:\/\/doi.org\/10.3350\/cmh.2021.0093.","journal-title":"Clin Mol Hepatol"},{"key":"1477_CR22","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3748\/wjg.v27.i21.2727","volume":"27","author":"EP Tsounis","year":"2021","unstructured":"Tsounis EP, Tourkochristou E, Mouzaki A, Triantos C. Toward a new era of hepatitis B virus therapeutics: the pursuit of a functional cure. World J Gastroenterol. 2021;27:2727\u201357. https:\/\/doi.org\/10.3748\/wjg.v27.i21.2727.","journal-title":"World J Gastroenterol"},{"key":"1477_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3760\/cma.j.issn.1674-2397.2024.04.003","volume":"17","author":"Ma Yilin","year":"2024","unstructured":"Yilin Ma. Research and development of major new antiviral drugs for chronic hepatitis B. Chin J Clin Infect Dis. 2024;17:263\u201382. https:\/\/doi.org\/10.3760\/cma.j.issn.1674-2397.2024.04.003.","journal-title":"Chin J Clin Infect Dis."},{"issue":"6","key":"1477_CR24","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3969\/j.issn.1001-5256.2022.06.035","volume":"38","author":"Y Liu","year":"2022","unstructured":"Liu Y, Chen X. Advances in the research and development of new drugs for chronic hepatitis B. J Clin Hepatol. 2022;38(6):1387\u201392. https:\/\/doi.org\/10.3969\/j.issn.1001-5256.2022.06.035.","journal-title":"J Clin Hepatol."},{"key":"1477_CR25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jhep.2022.12.014","volume":"78","author":"L Wang","year":"2023","unstructured":"Wang L, Zhu Q, Zhang JD, Zhang Y, Ni X, Xiang K, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2023;78:742\u201353. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.014.","journal-title":"J Hepatol"},{"key":"1477_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102112","volume":"35","author":"EM Smekalova","year":"2023","unstructured":"Smekalova EM, Martinez MG, Combe E, Kumar A, Dejene S, Leboeuf D, et al. Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo. Mol Ther Nucleic Acids. 2023;35:102112. https:\/\/doi.org\/10.1016\/j.omtn.2023.102112.","journal-title":"Mol Ther Nucleic Acids."},{"key":"1477_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1021\/acsmedchemlett.4c00037","volume":"15","author":"D Kato","year":"2024","unstructured":"Kato D, Choy RW-Y, Canales E, Dick RA, Lake AD, Shapiro ND, et al. Discovery of hepatitis B virus surface antigen suppressor GS-8873. ACS Med Chem Lett. 2024;15:546\u201354. https:\/\/doi.org\/10.1021\/acsmedchemlett.4c00037.","journal-title":"ACS Med Chem Lett"},{"key":"1477_CR28","doi-asserted-by":"publisher","unstructured":"Nakcheol Jeong. The discovery of AMS-I-1274, a high potent and orally active capsid-assembly modulator against hepatitis B virus. J Hepatol. 2022. https:\/\/doi.org\/10.1016\/S0168-8278(22)02028-1.","DOI":"10.1016\/S0168-8278(22)02028-1"},{"key":"1477_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1021\/acsmedchemlett.2c00002","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Zhang Z, Chen Y, Wang B, Yang G, Xu X, et al. Discovery of SHR5133, a highly potent and novel HBV capsid assembly modulator. ACS Med Chem Lett. 2022;13:507\u201312. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00002.","journal-title":"ACS Med Chem Lett"},{"key":"1477_CR30","doi-asserted-by":"publisher","first-page":"8844061","DOI":"10.1155\/2020\/8844061","volume":"2020","author":"R Kalkeri","year":"2020","unstructured":"Kalkeri R, Peng J, Huang C, Cai Z, Ptak RG, Suto MJ. HBV core promoter inhibition by tubulin polymerization inhibitor (SRI-32007). Adv Virol. 2020;2020:8844061. https:\/\/doi.org\/10.1155\/2020\/8844061.","journal-title":"Adv Virol"},{"key":"1477_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01348-22","volume":"67","author":"D Burdette","year":"2023","unstructured":"Burdette D, Hyrina A, Song Z, Beran RK, Cheung T, Gilmore S, et al. Characterization of a novel capsid assembly modulator for the treatment of chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2023;67:e0134822. https:\/\/doi.org\/10.1128\/aac.01348-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"1477_CR32","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1021\/acsinfecdis.8b00269","volume":"5","author":"X Zhang","year":"2019","unstructured":"Zhang X, Cheng J, Ma J, Hu Z, Wu S, Hwang N, et al. Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors. ACS Infect Dis. 2019;5:759\u201368. https:\/\/doi.org\/10.1021\/acsinfecdis.8b00269.","journal-title":"ACS Infect Dis"},{"key":"1477_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00535-023-02070-y","volume":"59","author":"T Watanabe","year":"2024","unstructured":"Watanabe T, Hayashi S, Zhaoyu Y, Inada H, Nagaoka K, Tateyama M, et al. A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA. J Gastroenterol. 2024;59:315\u201328. https:\/\/doi.org\/10.1007\/s00535-023-02070-y.","journal-title":"J Gastroenterol"},{"key":"1477_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01686-21","volume":"96","author":"T Takemori","year":"2022","unstructured":"Takemori T, Sugimoto-Ishige A, Nishitsuji H, Futamura Y, Harada M, Kimura-Someya T, et al. Establishment of a monoclonal antibody against human NTCP that blocks hepatitis B virus infection. J Virol. 2022;96:e0168621. https:\/\/doi.org\/10.1128\/jvi.01686-21.","journal-title":"J Virol"},{"key":"1477_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/v16030323","volume":"16","author":"AM Lam","year":"2024","unstructured":"Lam AM, Dugyala RR, Sheraz M, Liu F, Thi EP, Graves IE, et al. Preclinical antiviral and safety profiling of the HBV RNA destabilizer AB-161. Viruses. 2024;16:323. https:\/\/doi.org\/10.3390\/v16030323.","journal-title":"Viruses"},{"key":"1477_CR36","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1002\/hep.32697","volume":"76","author":"T Watanabe","year":"2022","unstructured":"Watanabe T, Hayashi S, Nagaoka K. A novel, small anti-HBV compund reduces HBsAg and HBV DNA by destabilizing HBV RNA. Hepatology. 2022;76:S270. https:\/\/doi.org\/10.1002\/hep.32697.","journal-title":"Hepatology"},{"key":"1477_CR37","doi-asserted-by":"publisher","first-page":"S1164","DOI":"10.1016\/S0168-8278(23)03306-8","volume":"78","author":"A Rubio","year":"2023","unstructured":"Rubio A, Deshpande A, Walsh R, Netter H, Lee CL, Hammond R, et al. SAT-191: a monoclonal antibody 4G2 exhibits anti-viral activity in mouse models of chronic hepatitis B. J Hepatol. 2023;78:S1164. https:\/\/doi.org\/10.1016\/S0168-8278(23)03306-8.","journal-title":"J Hepatol"},{"issue":"S1","key":"1477_CR38","doi-asserted-by":"publisher","first-page":"S571","DOI":"10.1097\/HEP.0000000000001077","volume":"80","author":"A Deshpande","year":"2024","unstructured":"Deshpande A, Netter H, Walsh R. CLB-405 and CLB-505 combined with a saponin based adjuvant TQL-1055 exhibits a strong antiviral and enhanced immune responses in a mouse model of persistent hepatitis B infection. Hepatology. 2024;80(S1):S571\u20132. https:\/\/doi.org\/10.1097\/HEP.0000000000001077.","journal-title":"Hepatology"},{"key":"1477_CR39","doi-asserted-by":"publisher","first-page":"S582","DOI":"10.1097\/HEP.0000000000000580","volume":"78","author":"E Str\u00e4ngberg","year":"2023","unstructured":"Str\u00e4ngberg E, Bonn B, Phan P. Preclinical characterization of the novel, orally bioavailable NTCP inhibitor A7387. Hepatology. 2023;78:S582. https:\/\/doi.org\/10.1097\/HEP.0000000000000580.","journal-title":"Hepatology"},{"key":"1477_CR40","unstructured":"GSK. Pipeline. https:\/\/www.gsk.com\/en-gb\/innovation\/pipeline\/. Accessed 20 Aug 2025."},{"key":"1477_CR41","unstructured":"Chipscreen. Other products under development. Available from: https:\/\/www.chipscreen.com\/products\/1282.html. [Accessed 20 Aug 2025]."},{"key":"1477_CR42","unstructured":"SCG CELL-Our Science. https:\/\/www.scgcell.com\/kxjs. Accessed 20 Aug 2025."},{"key":"1477_CR43","unstructured":"Shanghai Zhimeng Pharmaceutical Technology Co., Ltd. Pipeline. https:\/\/core-biopharma.com\/pipeline.html. Accessed 20 Aug 2025."},{"key":"1477_CR44","unstructured":"Excision Biotherapeutics Inc. Pipeline. 2025. https:\/\/www.excision.bio\/technology\/pipeline. Accessed 20 Aug 2025."},{"key":"1477_CR45","unstructured":"nChroma bio. https:\/\/www.nchromabio.com\/. Accessed 20 Aug 2025."},{"key":"1477_CR46","unstructured":"Hbvtech Technologies. https:\/\/www.hbvtech.com\/products. Accessed 20 Aug 2025."},{"key":"1477_CR47","unstructured":"LionTCR. Pipeline. https:\/\/www.liontcr.com\/pipeline. Accessed 20 Aug 2025."},{"key":"1477_CR48","unstructured":"OliX. https:\/\/www.olixpharma.com\/eng\/rnd\/rnd03_olx703a.php. Accessed 20 Aug 2025."},{"key":"1477_CR49","unstructured":"Kawin. Innovative_Kein Technology. https:\/\/www.kawin.com.cn\/Innovative\/#32. Accessed 20 Aug 2025."},{"key":"1477_CR50","unstructured":"Suzhou Shian Biotechnology Co., Ltd. https:\/\/www.siranbio.com\/page\/cpgx\/. Accessed 20 Aug 2025."},{"key":"1477_CR51","unstructured":"U-mab Biopharma. Pipeline. https:\/\/www.umab-biopharma.com\/yfgx. Accessed 20 Aug 2025."},{"key":"1477_CR52","unstructured":"AlloVir. ALVR107: hepatitis B virus (HBV) therapy. https:\/\/www.allovir.com\/products\/alvr107. Accessed 20 Aug 2025."},{"key":"1477_CR53","unstructured":"Asher Bio. AB359. https:\/\/asherbio.com\/pipeline\/ab359\/. Accessed 20 Aug 2025."},{"key":"1477_CR54","unstructured":"Chengdu Fanuoxi Biopharmaceutical Technology Co., Ltd. https:\/\/www.fanoxi.com\/page80. Accessed 20 Aug 2025."},{"key":"1477_CR55","unstructured":"Kami Biopharmaceuticals (Chengdu) Co., Ltd. Products. https:\/\/www.chimigen.com\/cpyyf. Accessed 20 Aug 2025."},{"key":"1477_CR56","unstructured":"Prazer Therapeutics. http:\/\/prazertx.com\/. Accessed 20 Aug 2025."},{"key":"1477_CR57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000360948","volume":"57","author":"FA Lempp","year":"2014","unstructured":"Lempp FA, Urban S. Inhibitors of hepatitis B virus attachment and entry. Intervirology. 2014;57:151\u20137. https:\/\/doi.org\/10.1159\/000360948.","journal-title":"Intervirology"},{"key":"1477_CR58","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41467-023-36219-3","volume":"14","author":"L Lecoq","year":"2023","unstructured":"Lecoq L, Brigandat L, Huber R, Fogeron M-L, Wang S, Dujardin M, et al. Molecular elucidation of drug-induced abnormal assemblies of the hepatitis B virus capsid protein by solid-state NMR. Nat Commun. 2023;14:471. https:\/\/doi.org\/10.1038\/s41467-023-36219-3.","journal-title":"Nat Commun"},{"key":"1477_CR59","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1021\/acs.jmedchem.1c02040","volume":"65","author":"A Pavlova","year":"2022","unstructured":"Pavlova A, Bassit L, Cox BD, Korablyov M, Chipot C, Patel D, et al. The mechanism of action of hepatitis B virus capsid assembly modulators can be predicted from binding to early assembly intermediates. J Med Chem. 2022;65:4854\u201364. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02040.","journal-title":"J Med Chem"},{"key":"1477_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1090237","author":"L Zhang","year":"2022","unstructured":"Zhang L, Liang Y, Liang G, Tian Z, Zhang Y, Liu Z, Ji X. The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates. Front Pharmacol. 2022;13:1090237. https:\/\/doi.org\/10.3389\/fphar.2022.1090237.","journal-title":"Front Pharmacol"},{"key":"1477_CR61","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/microorganisms12030599","volume":"12","author":"L Sneller","year":"2024","unstructured":"Sneller L, Lin C, Price A, Kottilil S, Chua JV. RNA interference therapeutics for chronic hepatitis B: progress, challenges, and future prospects. Microorganisms. 2024;12:599. https:\/\/doi.org\/10.3390\/microorganisms12030599.","journal-title":"Microorganisms."},{"key":"1477_CR62","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.3390\/v14092052","volume":"14","author":"A Vaillant","year":"2022","unstructured":"Vaillant A. Oligonucleotide-based therapies for chronic HBV infection: a primer on biochemistry, mechanisms and antiviral effects. Viruses. 2022;14:2052. https:\/\/doi.org\/10.3390\/v14092052.","journal-title":"Viruses"},{"key":"1477_CR63","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jhep.2015.11.032","volume":"64","author":"G Billioud","year":"2016","unstructured":"Billioud G, Kruse RL, Carrillo M, Whitten-Bauer C, Gao D, Kim A, et al. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides. J Hepatol. 2016;64:781\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.032.","journal-title":"J Hepatol"},{"key":"1477_CR64","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/cei.13614","volume":"205","author":"T Cargill","year":"2021","unstructured":"Cargill T, Barnes E. Therapeutic vaccination for treatment of chronic hepatitis B. Clin Exp Immunol. 2021;205:106\u201318. https:\/\/doi.org\/10.1111\/cei.13614.","journal-title":"Clin Exp Immunol"},{"key":"1477_CR65","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3389\/fimmu.2020.00401","volume":"11","author":"RC Hoogeveen","year":"2020","unstructured":"Hoogeveen RC, Boonstra A. Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection. Front Immunol. 2020;11:401. https:\/\/doi.org\/10.3389\/fimmu.2020.00401.","journal-title":"Front Immunol"},{"key":"1477_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2022.101205","volume":"53","author":"M Beretta","year":"2022","unstructured":"Beretta M, Mouquet H. Advances in human monoclonal antibody therapy for HBV infection. Curr Opin Virol. 2022;53:101205. https:\/\/doi.org\/10.1016\/j.coviro.2022.101205.","journal-title":"Curr Opin Virol"},{"key":"1477_CR67","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3390\/biomedicines10081861","volume":"10","author":"P Mokhtary","year":"2022","unstructured":"Mokhtary P, Pourhashem Z, Mehrizi AA, Sala C, Rappuoli R. Recent progress in the discovery and development of monoclonal antibodies against viral infections. Biomedicines. 2022;10:1861. https:\/\/doi.org\/10.3390\/biomedicines10081861.","journal-title":"Biomedicines."},{"key":"1477_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00430-014-0370-1","volume":"204","author":"E Zhang","year":"2015","unstructured":"Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol. 2015;204:11\u201320. https:\/\/doi.org\/10.1007\/s00430-014-0370-1.","journal-title":"Med Microbiol Immunol"},{"key":"1477_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104824","volume":"180","author":"Y Xia","year":"2020","unstructured":"Xia Y, Guo H. Hepatitis B virus cccDNA: formation, regulation and therapeutic potential. Antiviral Res. 2020;180:104824. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104824.","journal-title":"Antiviral Res"},{"key":"1477_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.64","volume":"3","author":"H-C Yang","year":"2014","unstructured":"Yang H-C, Kao J-H. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microbes Infect. 2014;3:e64. https:\/\/doi.org\/10.1038\/emi.2014.64.","journal-title":"Emerg Microbes Infect"},{"key":"1477_CR71","doi-asserted-by":"publisher","first-page":"12472","DOI":"10.1128\/JVI.01123-07","volume":"81","author":"H Guo","year":"2007","unstructured":"Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo J-T. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol. 2007;81:12472\u201384. https:\/\/doi.org\/10.1128\/JVI.01123-07.","journal-title":"J Virol"},{"key":"1477_CR72","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/v13050757","volume":"13","author":"J Diogo Dias","year":"2021","unstructured":"Diogo Dias J, Sarica N, Neuveut C. Early steps of hepatitis B life cycle: from capsid nuclear import to cccDNA formation. Viruses. 2021;13:757. https:\/\/doi.org\/10.3390\/v13050757.","journal-title":"Viruses"},{"key":"1477_CR73","unstructured":"Challener C. Accelerating discovery and development with advances in high-throughput screening. Pharm Technol 2024;48(11):12\u20136."},{"key":"1477_CR74","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3390\/ijms13010427","volume":"13","author":"P Szyma\u0144ski","year":"2011","unstructured":"Szyma\u0144ski P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-yhroughput screening in drug discovery: toxicological screening tests. Int J Mol Sci. 2011;13:427\u201352. https:\/\/doi.org\/10.3390\/ijms13010427.","journal-title":"Int J Mol Sci"},{"key":"1477_CR75","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1038\/s41596-020-00403-2","volume":"15","author":"CB Gurumurthy","year":"2020","unstructured":"Gurumurthy CB, Quadros RM, Richardson GP, Poluektova LY, Mansour SL, Ohtsuka M. Genetically modified mouse models to help fight COVID-19. Nat Protoc. 2020;15:3777\u201387. https:\/\/doi.org\/10.1038\/s41596-020-00403-2.","journal-title":"Nat Protoc"},{"key":"1477_CR76","unstructured":"John McHutchison. Assembly bio announces decision to discontinue clinical development of ABI-H2158. Assem Bio 2021. https:\/\/www.assemblybio.com\/news\/assembly-bio-announces-decision-to-discontinue-clinical-development-of-abi-h2158\/. Accessed 20 Aug 2025."},{"key":"1477_CR77","unstructured":"EATG. Aligos discontinues development of its drug candidate ALG-020572 for the treatment of hepatitis B. https:\/\/www.eatg.org\/hiv-news\/aligos-discontinues-development-of-its-drug-candidate-alg-020572-for-the-treatment-of-hepatitis-b\/. Accessed 20 Aug 2025."},{"key":"1477_CR78","unstructured":"Adams B. Enanta dumps oral hep B program after safety warnings in early test | fierce biotech 2021. https:\/\/www.fiercebiotech.com\/biotech\/enanta-dumps-oral-hep-b-program-after-safety-warnings-early-test. Accessed 20 Aug 2025."},{"key":"1477_CR79","unstructured":"Arrowhead Pharmaceuticals Inc. Arrowhead pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi therapeutics. https:\/\/ir.arrowheadpharma.com\/news-releases\/news-release-details\/arrowhead-pharmaceuticals-focuses-resources-subcutaneous-and. Accessed 20 Aug 2025."},{"key":"1477_CR80","unstructured":"Biospace. Reeling from GlobeImmune hepatitis B termination, Gilead faces Merck & co., GlaxoSmithKline competition. 2016. https:\/\/www.biospace.com\/reeling-from-globeimmune-hepatitis-b-termination-gilead-faces-merck-and-co-glaxosmithkline-competition. Accessed 20 Aug 2025."},{"key":"1477_CR81","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/13543776.2025.2467699","volume":"35","author":"S Wang","year":"2025","unstructured":"Wang S, Ma F, Tang K, Xu S, Jia H, Liu X, et al. A patent review of hepatitis B virus core protein allosteric modulators (2019-present). Expert Opin Ther Pat. 2025;35:441\u201361. https:\/\/doi.org\/10.1080\/13543776.2025.2467699.","journal-title":"Expert Opin Ther Pat"},{"key":"1477_CR82","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"M-F Yuen","year":"2022","unstructured":"Yuen M-F, Lim S-G, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387:1957\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2210027.","journal-title":"N Engl J Med"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01477-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01477-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01477-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:36:37Z","timestamp":1758972997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01477-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01477-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. Bin Wu is an Editorial Board member of Clinical Drug Investigation. Bin Wu was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The authors declare no financial or non-financial competing interests with any pharmaceutical companies mentioned in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated from the simulation model are made available in the article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"BW conceived the study and are the guarantors. KJY, HF, and BW drafted the manuscript. MXY, YB, KJY, and YC collected and analyzed the data. BW revised and approved the final version of the manuscript. YC, WL, and HF participated in the data preparation and provided important comments on the manuscript. All authors read and approved the final manuscript and are accountable for all aspects of the work, including accuracy and integrity.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}